Free Trial
NASDAQ:MRVI

Maravai LifeSciences (MRVI) Stock Price, News & Analysis

$10.78
-0.27 (-2.44%)
(As of 05/23/2024 ET)
Today's Range
$10.71
$11.06
50-Day Range
$7.30
$11.34
52-Week Range
$4.52
$14.88
Volume
1.22 million shs
Average Volume
2.45 million shs
Market Capitalization
$2.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.44

Maravai LifeSciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
6.2% Upside
$11.44 Price Target
Short Interest
Bearish
6.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
1.06mentions of Maravai LifeSciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.15) to ($0.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

472nd out of 915 stocks

Pharmaceutical Preparations Industry

198th out of 399 stocks

MRVI stock logo

About Maravai LifeSciences Stock (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

MRVI Stock Price History

MRVI Stock News Headlines

Maravai LifeSciences Holdings, Inc. (MRVI)
Should You Sell Maravai LifeSciences (MRVI)?
MRVI Apr 2024 2.500 call
MRVI Apr 2024 2.500 put
Maravai LifeSciences Shares Rise 65% After 4Q Results
See More Headlines
Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2023
Today
5/23/2024
Next Earnings (Estimated)
8/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRVI
Fax
N/A
Employees
650
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.44
High Stock Price Target
$17.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+6.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$-119,030,000.00
Pretax Margin
218.84%

Debt

Sales & Book Value

Annual Sales
$288.95 million
Cash Flow
$0.09 per share
Book Value
$3.09 per share

Miscellaneous

Free Float
250,847,000
Market Cap
$2.71 billion
Optionable
Optionable
Beta
0.03
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Carl W. Hull (Age 65)
    Co-Founder & Executive Chairman
    Comp: $617.67k
  • Mr. William E. Martin III (Age 49)
    Chief Executive Officer
    Comp: $987.86k
  • Mr. Kevin M. Herde (Age 52)
    Executive VP & CFO
    Comp: $548.62k
  • Dr. Peter Michael Leddy Ph.D. (Age 61)
    Executive VP & Chief Administrative Officer
    Comp: $583.39k
  • Ms. Christine Dolan (Age 56)
    Executive VP & GM of Cygnus Technologies
    Comp: $536.63k
  • Mr. Andrew Burch (Age 55)
    President of Nucleic Acid Production
    Comp: $425.15k
  • Ms. Debra Hart
    Senior Director of Investor Relations
  • Mr. Kurt Oreshack (Age 43)
    Executive VP, General Counsel & Secretary
    Comp: $701.4k
  • Ms. Rebecca Buzzeo
    Executive VP & Chief Commercial Officer
  • Dr. Kate E. Broderick Ph.D.
    Chief Innovation Officer

MRVI Stock Analysis - Frequently Asked Questions

Should I buy or sell Maravai LifeSciences stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRVI shares.
View MRVI analyst ratings
or view top-rated stocks.

What is Maravai LifeSciences' stock price target for 2024?

10 brokers have issued 1 year price objectives for Maravai LifeSciences' shares. Their MRVI share price targets range from $7.00 to $17.00. On average, they predict the company's stock price to reach $11.44 in the next year. This suggests a possible upside of 6.2% from the stock's current price.
View analysts price targets for MRVI
or view top-rated stocks among Wall Street analysts.

How have MRVI shares performed in 2024?

Maravai LifeSciences' stock was trading at $6.55 at the beginning of 2024. Since then, MRVI shares have increased by 64.6% and is now trading at $10.78.
View the best growth stocks for 2024 here
.

When is Maravai LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our MRVI earnings forecast
.

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) released its earnings results on Monday, May, 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by $0.01. The business earned $79.03 million during the quarter, compared to analysts' expectations of $79.72 million. Maravai LifeSciences had a negative net margin of 47.81% and a negative trailing twelve-month return on equity of 4.28%. Maravai LifeSciences's revenue for the quarter was down 67.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.54 earnings per share.

What ETFs hold Maravai LifeSciences' stock?

ETFs with the largest weight of Maravai LifeSciences (NASDAQ:MRVI) stock in their portfolio include Morningstar US Small Growth (MSGR).Royce Quant Small-Cap Quality Value ETF (SQLV).

What guidance has Maravai LifeSciences issued on next quarter's earnings?

Maravai LifeSciences updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $265.0 million-$285.0 million, compared to the consensus revenue estimate of $271.8 million.

When did Maravai LifeSciences IPO?

Maravai LifeSciences (MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Who are Maravai LifeSciences' major shareholders?

Maravai LifeSciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include 12 West Capital Management LP (5.25%), Vanguard Group Inc. (3.99%), Bamco Inc. NY (0.84%), Clearbridge Investments LLC (0.32%), Principal Financial Group Inc. (0.16%) and Jennison Associates LLC (0.16%).

How do I buy shares of Maravai LifeSciences?

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRVI) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners